ClinicalTrials.Veeva

Menu

Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias

M

Medical University Innsbruck

Status

Unknown

Conditions

Covid19

Treatments

Other: questionnaire

Study type

Observational

Funder types

Other

Identifiers

NCT04649320
1264/2020

Details and patient eligibility

About

Cancer patients are among the most vulnerable individuals, whose health-related quality of life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the COVID-19 pandemic influences the life of cancer patients and how these patients cope with the additional distress with the aim to facilitate the development of improved future interventional strategies to maintain resilience and HRQOL

Full description

In December 2019, the novel human pathogenic virus "SARS-CoV2" from the coronavirus family was identified, causing a respiratory disease known as "COVID19" (coronavirus disease 2019). COVID19 manifests itself primarily with influenza-like symptoms, but in special cases it can lead to severe conditions such as ARDS (acute respiratory distress syndrome). Compared to other pulmotropic viruses such as the influenza virus, SARS-CoV-2 is associated with a higher contagiousness and mortality.

Haematological and oncological patients are particularly vulnerable due to their advanced age, immunological restrictions in the context of the underlying disease and the treatment modalities (chemotherapy, radiation therapy, ...).

To evaluate the effects of the COVID19 pandemic on the perception of patients with malignant diseases, we aim to record so-called "patient-reported outcomes" (PROs) from patients at the University Hospital of Innsbruck at the Department of Internal Medicine V (Hematology and Oncology) and at the Department for Radiotherapy and Radiation Oncology. We use the validated EORT QLQ-C30 and a specially developed questionnaire for COVID19.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18 years
  • validated hematological or oncological disease
  • informed consent

Exclusion criteria

  • Age < 18 years
  • Insufficient discernment

Trial design

300 participants in 1 patient group

cancer patients
Description:
adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
Treatment:
Other: questionnaire

Trial contacts and locations

1

Loading...

Central trial contact

Reinhard Stauder, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems